Effect of cytochrome P450 2C19 (CYP2C19) gene polymorphism and clopidogrel reactivity on long term prognosis of patients with coronary heart disease after PCI
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.CYP2C19 gene variations affect clopidogrel response in coronary heart disease patients undergoing PCI. Combining genetic testing with platelet reactivity improves prediction of major adverse cardiovascular events.
Area Of Science
- Pharmacogenomics
- Cardiovascular Medicine
- Interventional Cardiology
Background
- Clopidogrel is a key antiplatelet medication for patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).
- CYP2C19 gene polymorphism significantly influences clopidogrel metabolism and efficacy.
- Assessing clopidogrel reactivity and its genetic basis is crucial for optimizing treatment and patient outcomes.
Purpose Of The Study
- To investigate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity.
- To determine the association between clopidogrel low responsiveness (CLR) and long-term clinical outcomes in CHD patients post-PCI.
- To evaluate the predictive value of combining CYP2C19 genotyping with platelet reactivity for major adverse cardiovascular events (MACCEs).
Main Methods
- A cohort of 675 patients with CHD undergoing PCI was enrolled.
- Patients were categorized based on platelet inhibition rate into clopidogrel low responsiveness (CLR) and normal clopidogrel responsiveness (NCR) groups.
- CYP2C19 genotypes (normal, intermediate, poor metabolizers) were determined, and 12-month cumulative rates of death, MACCEs, and bleeding events were calculated.
Main Results
- Clopidogrel low responsiveness (CLR) was observed in 44.4% of patients.
- Significant differences in platelet inhibition rates were noted across CYP2C19 metabolic genotypes (P < 0.05).
- Patients with CLR or poor metabolizer genotype had a significantly higher incidence of MACCEs at 12 months (P < 0.05). A risk score combining these factors showed predictive value (AUC = 0.712).
Conclusions
- CYP2C19 gene polymorphism is correlated with clopidogrel low response in CHD patients.
- CYP2C19 genotyping combined with platelet reactivity assessment is an independent predictor of 12-month MACCEs after PCI.
- This combined approach offers superior prediction of MACCEs compared to either test alone.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...